StemCell Therapy

Global Pain Management Therapeutics Market: Snapshot

Pain is invariably around whenever a body is suffering from diseases, which can be of multiple types including fibromyalgia, stomach ulcer, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Even during and after the therapy, pain constitutes a major part of the procedure that the subject has to bear but with technological advancements, it has become possible to considerably reduce the suffering and manage the pain via a variety of physiological mechanism, targeting the nociceptors for example. As the investments on robust infrastructure escalates across various emerging and developed countries, and awareness regarding the availability of alternatives increase, the demand in the global pain management therapeutics market is projected to increment at a healthy CAGR during the forecast period of 2017 to 2025.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1724

Currently, the developed regions of North America and Europe serve the maximum demand in the pain management therapeutics market, although highly populated emerging economies in Asia Pacific such as India and China are expected to turn into a profitable market towards the end of the forecast period.

In the current scenario, the global pain management therapeutics market is highly competitive, with the leading players constantly striving to come up with new products that are more efficient and hence gives them an edge over their competitors. In the current scenario, Purdue Pharma LP and Pfizer lead the market with nearly half the global shares, although the likes of Depomed Inc. and AstraZeneca Plc gaining ground. There is a strong presence of conventional medicines for pain management, which will keep the competitive landscape saturated throughout the forecast period. In the near future, a number of medium and small generic drugs manufacturers are expected to have a foray into pain management therapeutics market too, which will further intensity the tussle for the pole position.

Pain Management Therapeutics Market: Overview

Pain management therapeutics comprise various methods to ease varied degrees of pain among patients and improve their quality of life. Pharmaceutical therapeutics are usually the first line of treatment for pain management and if this does not work, patients opt for other methods such as pain managing devices, physiotherapy, and chiropractic therapy.

Pain management therapeutics can be categorized into antidepressants, anticonvulsants, opioids, anesthetics, antimigraine agents, non-steroidal anti-inflammatory drugs (NSAIDS), and non-narcotic analgesics. Various drugs are used for the management of different kinds of pain, such as fibromyalgia, neuropathic pain, arthritic pain, chronic back pain, post-operative pain, migraine, and cancer-related pain. A common trend that has been observed among patients is the consumption of over-the-counter (OTC) drugs rather than prescription drugs.

Pain Management Therapeutics Market: Trends

The growing prevalence of chronic diseases such as diabetes and cancer has been single-handedly driving the demand for pain management therapeutics and the number of people suffering from this kind of pain has been surging at a substantial rate. In addition to this, a massive geriatric population susceptible to arthritis, nerve damage, neuropathy, and joint pain is also boosting the market for pain management therapeutics. Supplementing market growth are favorable regulatory scenarios in many developed countries around the world.

However, as more and more patients opt for generic pain management drugs, the branded segment has been suffering a major setback. Moreover, the patent expiries of a number of blockbuster drugs will have a significant impact on the overall market for pain management therapeutics.

Pain Management Therapeutics Market: Market Potential

Despite the fact that leading brands are nearing a point of saturation, the pain management therapeutics market possesses strong potential for growth, particularly for smaller players. For instance, looking to expand its footprint in the global market as well as strengthen its U.S. pharmaceutical unit, Ireland-based Endo International plc acquired Auxilium Pharmaceuticals in 2015. The company also launched the BELBUCA Bucccal Film in 2016, which is used for the management of chronic pain.

Purdue Pharma, headquartered in Connecticut, U.S., ventured into a patent agreement with Acura Pharmaceuticals, Inc. and Egalet Corporation in 2016 for the development and sales of opioid pain management medicines.

Pain Management Therapeutics Market: Regional Outlook

Geographically, the global market for pain management therapeutics comprises North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. North America and Europe hold the largest share in the overall market and are slated to continue their dominance throughout the forecast period. The rising consumption of advanced pain management drugs and the availability of well-established and sophisticated healthcare infrastructure are the key factors driving the North America and Europe pain management therapeutics market. Asia Pacific is an immensely lucrative region and a number of players are looking to expand their operations in the many emerging countries in the region. This can be attributed to strong economic growth in nations such as China, India, Malaysia, and Japan, rising investments in the healthcare industry in these countries, and the increasing affordability of the population.

Pain Management Therapeutics Market: Competitive Analysis

There are a host of generic as well as branded drug manufacturers in the global pain management therapeutics market. These include GlaxoSmithKline plc, Novartis AG, Johnson & Johnson, Abbott Laboratories, AstraZeneca, Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Purdue Pharma L.P., Endo Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Depomed, Inc., and Pfizer, Inc. Although companies producing branded pain management therapeutics have a strong foothold in the market, the market is actually dominated by generic drug manufacturers, giving small- and medium-scale players immense scope for growth.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/pain-management-therapeutics-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original here:
Pain Management Therapeutics Market Worldwide Survey On Product Need 2025 - Latest Herald

As of April 2020, there are 35 states that have legalizedmedicinal cannabis to some extent and of course, this varies greatly fromstate to state.

Despite the federal government keeping cannabis listed as a Schedule 1 narcotic, each state has the authority to create their own laws governing cannabis use within their borders. Most states allow the herb now, but the qualifying conditions that allow patients access to medical cannabis are different in each state. Use our guide to determine whether you qualify for medical cannabis in your home state.

*Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Click here for the full list and for any updates http://www.akleg.gov/basis/Bill/Plaintext/21?Hsid=SB0094E

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and post-traumatic stress disorder.

Click here for the full list and for any updates http://www.azleg.gov/viewdocument/?docName=http://www.azleg.gov/ars/36/02801.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and peripheral neuropathy.

Click here for the full list and for any updates http://www.healthy.arkansas.gov/Pages/MedMarijuana.aspx

**Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Any other chronic or persistent medical symptom that considerablylimits a persons abilities or diminishes their quality of life, as defined bythe Americans with Disabilities Act of 1990.

Click here for the full list and for any updates https://leginfo.legislature.ca.gov/faces/codes_displayText.xhtml?lawCode=HSC&division=10.&title=&part=&chapter=6.&article=2.5.

*Recreational cannabis is legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), persistent muscle spasms, seizures, severenausea, and severe pain, as well as any condition that is approved by a doctor.

Click here for the full list and for any updates https://www.colorado.gov/pacific/cdphe/qualifying-medical-conditions-medical-marijuana-registry

*Recreational cannabis is NOT legal in this state (although this will be up for a vote soon)

Qualifying medical conditions for cannabis include:

For underagepatients:

Click here for the full list and for any updates http://www.ct.gov/dcp/cwp/view.asp?q=509628&dcpNav=%7C

*Recreational cannabis is NOT legal in this state (although this will be up for a vote soon)

Qualifying medical conditions for cannabis include:

Any chronic or debilitating conditions including but notlimited to: cachexia (wasting syndrome), severe pain that has not responded toprescribed medication in 3 months, recurring nausea, muscle spasms, andmultiple sclerosis.

Click here for the full list and for any updates http://dhss.delaware.gov/dph/hsp/medmarpt.html

*Recreational cannabis is legal in this district

Qualifying medical conditions include:

Any other condition that is chronic, that could benefit frommedical cannabis (as determined on a case-by-case basis) and cannot beeffectively treated by standard medical practices.

Click here for the full list and for any updates: http://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/140523MMPRegulationsRevised.pdf

*Recreational cannabis is not legal in this state

Qualifying medical conditions for cannabis include:

Click here for the full list and for any updates http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0300-0399/0381/Sections/0381.986.html

*Recreational cannabis is not legal in this state

Qualifying medical conditions for cannabis include:

Any chronic or debilitating condition including but not limitedto: cachexia (wasting syndrome), severe pain, severe nausea, seizures, musclespasms, multiple sclerosis, and Crohns disease.

Click here to read the full list and for any updates http://health.hawaii.gov/medicalcannabisregistry/providers/debilitating-medical-conditions/

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Click here forthe full list and for any updates http://www.dph.illinois.gov/topics-services/prevention-wellness/medical-cannabis/debilitating-conditions

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for a full list and for any updates list of guidelines http://www.state.ia.us/odcp/docs/CBDFinalFactSheetIowaJune2014.pdf

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for a full list or for any updates http://ldh.la.gov/index.cfm/page/3633

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Sec. 19. 22 MRSA2423-B

Click here for afull list or for any updates https://legislature.maine.gov/legis/bills/bills_128th/billtexts/HP106001.asp

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here for the full list and for any updates http://mmcc.maryland.gov/Pages/patients.aspx

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Any other debilitating condition as determined by a qualified physician.

Clickhere for the full list and for any updates https://malegislature.gov/Laws/SessionLaws/Acts/2012/Chapter369

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

A chronic ordebilitating including but not limited to: cachexia (wasting disease), severeand chronic pain, severe nausea, seizures, muscle spasms, and multiplesclerosis.

Click here for thefull list or for any updates http://www.legislature.mi.gov/(S(vxeekwsfu2lon4z4ssftgnjt))/mileg.aspx?page=getObject&objectName=mcl-333-26423

*Recreational cannabis is not legal in this state

Qualifying medical conditions include:

Any other medical condition thats approved by the medicalcommissioner

Click here for the full list or for any updates http://www.health.state.mn.us/topics/cannabis/patients/conditions.html

*Recreational cannabis is not legal in this state

Qualifying medical conditions include:

Any other chronicor debilitating medical condition that can benefits from the use of medicalcannabis, as determined by a qualified physician.

Click here forthe full list or for any updates https://health.mo.gov/safety/medical-marijuana/faqs.php

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Click here forthe full list or for any updates http://dphhs.mt.gov/marijuana/mmpfaq#159692088-what-are-the-debilitating-conditions-for-which-i-can-recommend-marijuana-for-my-patients

*Recreational cannabis is legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates http://dpbh.nv.gov/Reg/MM-Patient-Cardholder-Registry/dta/FAQs/Medical_Marijuana_Patient_Cardholder_Registry_-_FAQs/

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://www.dhhs.nh.gov/oos/tcp/medical-conditions.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any chronic or debilitating condition including but notlimited to: cachexia (wasting syndrome), chronic pain, recurring nausea,epilepsy, multiple sclerosis, and peripheral neuropathy.

Click here for the full list and for any updates http://nj.gov/health/medicalmarijuana/pat_faqs.shtml#7

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://nmhealth.org/publication/view/form/135/

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates http://www.health.ny.gov/regulations/medical_marijuana/faq.htm

*Recreational cannabis is NOT legal in this state

Qualifying medical conditions include:

Any other chronic or debilitating medical condition that canbenefit from the use of medical cannabis, as determined by a qualifiedphysician.

Click here for the full list or for any updates https://www.legis.nd.gov/assembly/65-2017/documents/17-0630-05000.pdf

*Recreational cannabis is NOT legal in this state

The rest is here:
What Are The Qualifying Medical Conditions For Cannabis In Your State? - CBD Testers

Optic Neuropathy Pipeline Review, H1 2019>This report offers a detailed view of market opportunity by end user segments, product segments, sales channels, key countries, and import / export dynamics. It details market size & forecast, growth drivers, emerging trends, market opportunities, and investment risks in over various segments in Optic Neuropathy industry. It provides a comprehensive understanding of Optic Neuropathy market dynamics in both value and volume terms.

The key players covered in this study > Allergan Plc, Antoxis Ltd, Quark Pharmaceuticals Inc, Recursion Pharmaceuticals Inc, Regenera Pharma Ltd, Regeneron Pharmaceuticals Inc

The final report will add the analysis of the Impact of Covid-19 in this report Optic Neuropathy industry.

Get Sample Copy of the Complete Report

This report focuses on the global Optic Neuropathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Optic Neuropathy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Table Of Content

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 North America

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

This report studies the Optic Neuropathy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Optic Neuropathy market by product type and applications/end industries.

Customization of this Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. For more relevant reports visitwww.reportsandmarkets.com

What to Expect From This Report on Optic Neuropathy Market:

The developmental plans for your business based on the value of the cost of the production and value of the products, and more for the coming years.

A detailed overview of regional distributions of popular products in the Optic Neuropathy Market.

How do the major companies and mid-level manufacturers make a profit within the Optic Neuropathy Market?

Estimate the break-in for new players to enter the Optic Neuropathy Market.

Comprehensive research on the overall expansion within the Optic Neuropathy Market for deciding the product launch and asset developments.

If U Know More about This Report

Any special requirements about this report, please let us know and we can provide custom report.

About Us:

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

For more detailed information please contact us at:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

More here:
Optic Neuropathy Market by Top Manufacturers with Production, Price, Revenue (value) and Market Share to 2026 - Latest Herald

Peripheral neuropathy is a common complication of primary Sjgren syndrome and may be associated with a diminished health-related quality of life (HR-QoL), according to research results published in Rheumatology International.

Researchers sought to compare HR-QoL outcomes in patients with primary Sjgren syndrome, both with and without peripheral neuropathy. They also aimed to examine the associations between the neurologic complications and components of HR-QoL outcomes using the 36-item Short Form Health Survey (SF-36). Overall, 50 adult patients with primary Sjgren syndrome (median age, 57.5 years; 96% women) were included in the study.

Of the total cohort, 80% (n=40) reported subjective symptoms, including paresthesia or other symptoms that were suggestive of neuropathic pain on a periodic or permanently present basis. In total, 46% (n=23) of patients met the criteria for a diagnosis of peripheral neuropathy (PNS+); the remaining patients were referred to as PNS-.

Researchers indicated the most common peripheral nervous system manifestation to be sensorimotor neuropathy, which was present in 47% of patients who were PNS+. Mononeuropathy was present in 26%, pure axonal sensory neuropathy, axonal motor neuropathy, and small fiber neuropathy were each present in 4.3%, and cranial nerve involvement was present in 17.4% of patients who were PNS+; 1 patient experienced both cranial and sensorimotor neuropathy. Among 35% of patients who were PNS+, neurologic symptoms preceded patients diagnosis of primary Sjgren syndrome.

Investigators studied data from both groups of patients in terms of clinical characteristics and laboratory testing results, and observed similarity in age, disease duration, time from diagnosis, and time of symptom onset. Clinical manifestations, including parotid enlargement, respiratory tract involvement, lymphadenopathy, and hypocomplementemia were significantly more prevalent among patients who were PNS+ vs those who were PNS- (74% vs 44%; 65% vs 37%; 61% vs 19%; and 26% vs 7%, respectively). In addition, patients in the PNS+ vs PNS- group were statistically significantly more likely to frequently use cyclophosphamide because of extraglandular manifestations (17% vs 0%, respectively).

Both groups were also compared based on the results of the visual analog scale (VAS)-pain scale, SF-36, and an interview regarding pain type. Among patients who were PNS+ vs PNS-, median VAS-pain was 3 vs 0, respectively (range, 0-7; P =.229). Neuropathic type pain was often observed across both subgroups but was predominantly among patients who were PNS+ compared with those who were PNS- (70% vs 41%).

Across the 5 domains of the SF-36, patients who were PNS+ vs PNS- had significantly lower results in terms of physical and emotional roles, vitality, bodily pain, and general health (P .05).

Study limitations included potential referral bias in patient selection, researchers inability to conduct neurophysiologic testing in individuals suspected of pure small-fiber neuropathy, and a lack of unambiguous differentiation between Sjgren syndrome-related neuropathy and other forms of neuropathy.

Our study showed that peripheral nervous involvement is frequent in [patients with primary Sjgren syndrome] and it is correlated with worse HR-QoL, the researchers concluded. To get the complete picture of [patients with Sjgren syndrome], a holistic approach starting with a comprehensive assessment of disease activityis needed.

Reference

Jasklska M, Chylinska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjgrens syndrome: A preliminary report [published online March 14, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04543-2

Go here to see the original:
Peripheral Neuropathy Is Common, Associated With Diminished Health-Related Quality of Life in Sjgren Syndrome - Rheumatology Advisor

Dont be surprised if the next time you see Elias Theodorou compete, hes a different fighter than he was in the UFC.

The Spartan parted ways with the promotion last May coming off of a loss to Derek Brunson at UFC Ottawa, despite that being his first loss in four fights and his overall UFC record standing at 8-3. In those 11 appearances, Theodorou only logged two finishes his last in March 2015 and that lack of an exclamation point on his performances may have contributed to his departure.

In February, Theodorou became the first MMA fighter to receive a therapeutic use exemption for medical cannabis, which was granted to him by the British Columbia Athletic Commission. The 31-year-old Canadian has long been an advocate for the use of cannabis as a medical treatment and he has used it to help him to deal with bilateral neuropathy pain that affects his arms and hands.

Theodorous condition influenced his approach to his UFC fights, with cannabis strictly prohibited in competition under USADA guidelines, and he spoke about how much being able to self-medicate will benefit him in the future.

I have bilateral neuropathy, so nerve damage of my upper extremities, Theodorou said on Mondays episode of The A-Side live chat. My actual hands are where the issues are and a lot of my fighting style over the last couple of days was actually taking that into account and moving around it.

Now, being able to medicate and not having those flare-ups that I normally have, because again putting your body through not only training and the condition that I already have and also the weight cut itself inhibits my ability to compete at a level playing field.

Theodorou said that medical cannabis is useful both for calming his nerves and dealing with the pain management of a competitive fighting career. Athletes in pro sports are often prescribed opioids, pain killers, and other drugs to address their maladies, and Theodorou believes adding cannabis to that list is a matter of medical equality.

While he may have utilized different tactics inside the octagon with his bilateral neuropathy unchecked, Theodorou isnt blaming his three UFC losses on not being allowed to medicate with cannabis.

I fought some really tough guys and I won more than Ive lost many times over, Theodorou said. The ones that I lost I wouldnt chalk it up to anything in regards to inability to medicate. Each individual fight is each individual situation, so Id never use an excuse, the better man won I would say. But again, the only people that Ive ever lost to were top-10 in the world at the time, and one of those persons happened to be Thiago Santos. Even in that situation I was able to take everything he threw at me and never quit.

One of the things I was able to learn from it is that even as a professional fighter, fight or flight is kind of still ingrained in us. Even when push comes to shove, I can still fight under the worst situations and in the bloodiest of wars.

In celebration of 4/20 the April 20 celebration widely recognized by cannabis culture Theodorou was hoping to fight in April in British Columbia, where he was granted his exemption, though a bout was never finalized. Wherever he competes next, Theodorou is optimistic that his TUE will carry over to other jurisdictions.

Because of the way that the whole system works in regards to the commissions, now that I got a therapeutic use exemption in one jurisdiction, most if not all should validate my exemption because of the way it all works out, Theodorou said. The case in point would be if someone got suspended for steroid use and they were suspended for a year in, lets say, New York, California wouldnt allow them to get registered until their suspension is over.

Well, the same thing happens in positive rulings. Thats the case in regards to my therapeutic use exemption. Theres already preliminary conversations with other commissions that, again, once I get a fight booked in that area theyll most likely validate my therapeutic use exemption. Obviously, it was a lot of hard work and it was able to [happen] because of me arguing my fundamental Canadian right to medicate as prescribed by my doctor in B.C., but now because of that ruling Im able to take that precedent and run with it not only in B.C. but everywhere else I fight.

Theodorou has already fought once since leaving the UFC, picking up a third-round finish against fellow big show vet Hernani Perpetuo at a show in Windsor, Ontario, last December. According to Theodorou, he was not tested for cannabis ahead of that fight and being able to self-medicate made a world of difference.

In reality, that was the first fight I was able to medicate as prescribed by my doctor and obviously, the results show for themselves, Theodorou said. Competing at the highest level at the way I was because of the strict testing, in many ways I was competing at a disadvantage compared to other athletes that can medicate as prescribed by their doctors. So now with the TUE and other avenues to compete on a competitive playing field, Im excited to keep that win streak going and smash the next person that stands in front of me.

See the rest here:
Elias Theodorou: Fighting style was affected by bilateral neuropathy before receiving cannabis TUE - MMA Fighting

Analysis Report on Neuropathic Pain Management Market

A report on global Neuropathic Pain Management market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Neuropathic Pain Management Market.

Request Sample Report @https://www.mrrse.com/sample/8659?source=atm

Some key points of Neuropathic Pain Management Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Neuropathic Pain Management Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Neuropathic Pain Management Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Neuropathic Pain Management market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Neuropathic Pain Management market is analyzed and depicted in the report.

The global Neuropathic Pain Management market segment by manufacturers include

Segmented as Follows:

This report covers the global neuropathic pain management market performance in terms of revenue contribution from various segments. The report begins with an overview of the neuropathic pain management and its definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the neuropathic pain management market along with detailing its opportunity analysis.

The global neuropathic pain management market is segmented based on drug class, indication, distribution channel and region. On the basis of drug class, the market has been segmented as tricyclic anti-depressants anticonvulsants, serotoninnorepinephrine reuptake inhibitor, capsaicin cream, local anaesthesia, opioids, steroids and others.

On the basis of indication, the market is segmented as diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others.

On the basis of distribution channel, the market is segmented as hospital pharmacies, retail pharmacies and online pharmacies.

A detailed analysis has been provided for each region in terms of market size, BPS analysis, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The regional market dynamics provide the key growth driver, restraints, and trends pertaining to each region. The forecast of the neuropathic pain management market by country, drug class, indication, distribution channel are represented in the tabular form for each region. This section also helps to understand the opportunity of the neuropathic pain management market in major countries by each segment.

In the next section of the report, the Competitive Landscape is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the market segments. Detailed profiles of players in the neuropathic pain management market are also provided in the report, which highlights company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the market outlook for 20182026 and sets the forecast within the context of the neuropathic pain management market by region. The key regions assessed in this report include North America, Latin America, Europe, Asia Pacific and MEA. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index.

The above sections by drug class, indication, distribution channel evaluate the historic market analysis for the period of 20132017 and growth prospects of the neuropathic pain management market for the period 20182026. We have considered 2016 as the base year and provided data for the forecast period.

The final section of report represents the global scenario for the neuropathic pain management market along with Y-o-Y growth and market forecast till 2026. This section also evaluates the global market opportunity over the forecast period and also the absolute dollar opportunity for each year. This section will help to understand the overall market growth of the neuropathic pain management market and the opportunity analysis for each year over the forecast period.

Bottom-up approach is used to validate the total market size obtained. The forecast presented in the report provides total revenue of the neuropathic pain management market over 20182026. While forecasting the market size, we have considered the impact of several factors such product approvals for neuropathic pain management, R&D investment by major players, pipeline analysis, penetration of products in different distribution channel, generic penetration across all regions, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/8659?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Neuropathic Pain Management economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/8659?source=atm

Benefits of Purchasing Neuropathic Pain Management Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read the original post:
COVID-19: Responding to the business impacts of Neuropathic Pain Management Revenue Growth Predicted by 2019-2028 - Jewish Life News

Pain is inevitable but can be managed This often results in a way of numbness, or lack of sensation. However, in some cases when this technique is injured, individuals experience pain within the affected region. Neuropathic pain doesnt start abruptly or resolve quickly; its a chronic condition that results in persistent pain symptoms. for several patients, the intensity of their symptoms can wax and wane throughout the day. Although neuropathic pain is assumed to be related to peripheral nerve problems, like neuropathy caused by diabetes or spinal stenosis, injuries to the brain or medulla spinalis also can cause chronic neuropathic pain.

Neuropathic pain is often contrasted to nociceptive pain, which is that the sort of pain which occurs when someone experiences an acute injury, like smashing a finger with a hammer or stubbing a toe when walking barefoot. this sort of pain is usually short-lived and typically quite aware of common pain medications in contrast to neuropathic pain.

Tramadol is a medication that is available online and can be used to relieve pain.

Tramadol without prescription in USA is available on the web if you want to check it out

Anything that results in loss of function within the sensory systema nervosum can cause neuropathic pain. As such, nerve problems from carpal tunnel syndrome or similar conditions can trigger neuropathic pain. Trauma, causing nerve injury, can cause neuropathic pain. Other conditions that may predispose patients to develop neuropathic pain include diabetes, vitamin deficiencies, cancer, HIV, stroke, MS, shingles, and cancer treatments.

Neuropathic pain may be a painful condition thats usually chronic. Its usually caused by chronic, progressive nerve disease, and it also can occur because of the results of injury or infection.

If youve got chronic neuropathic pain, it can flare up at any time without a clear pain-inducing event or factor. Acute neuropathic pain, while uncommon, can occur.

Typically, non-neuropathic pain (nociceptive pain) is thanks to an injury or illness. for instance, if you drop an important book on your foot, your system a Nervo sum sends signals of pain immediately after the book hits.

With neuropathic pain, the pain isnt typically triggered by an occasion or injury.

People with this painful condition may experience shooting, burning pain. The pain could also be constant or may occur intermittently. a sense of numbness or a loss of sensation is common, too.

Neuropathic pain tends to urge worse over time. About 1 in 3 Americans experience chronic pain. Of those, 1 in 5 experience neuropathic pain.A 2014 study estimated that as many as 10 percents of USA citizens experience some sort of neuropathic pain.

Understanding the possible causes can assist you to find better treatments and ways to stop the pain from getting worse over time.Nerve Pain & Nociceptive PainYou can have nerve pain and nociceptive pain together. Both pain types are often caused by an equivalent condition.

Nerve pain is a smaller amount likely than nociceptive pain to be helped by traditional painkillers like paracetamol, anti-inflammatories, and codeine. However, other sorts of medicines often work well to ease the pain. Nerve pain is usually eased by anti-depressant or anti-epileptic medicines. Please ask your doctor for more advice.

There are pain medication like Tramadol COD available from many online pharmacies and can be bought easily

View original post here:
Nerve Pain: Know Everything About it - Living Gossip

Multiple disease categories will be covered during this 2 1/2-day course, which will focus on diagnosis, treatment, image-guided diagnostic and therapeutic procedures, indications for surgery, and evaluation of the post-operative patient.

At the conclusion of this activity, participants should be able to:

-Identify key imaging findings in spine trauma and other spine emergencies

-Understand imaging techniques and observations in peripheral neuropathy, vascular diseases of the spine and spinal cord lesions, spine infections and spine tumors.

-Describe degenerative changes in the spine and the radiologists role in diagnosis of spine conditions and pain management.

-Understand the basics of Regenerative Medicine

-Be familiar with advanced imaging techniques of the spine including diffusion imaging and fMRI.

-Know what the spine surgeon is looking for in the preoperative and postoperative imaging studies.

URLs:Website:https://go.evvnt.com/643445-0?...Tickets:https://go.evvnt.com/643445-1?...

Date and Time: On Thursday March 04, 2021 at 7:00 am (ends Saturday March 06, 2021 at 10:00 am)

Category: Conferences | Science, Health and Medicine | CME (Continuing Medical Education)

Prices:Practicing Physician/Industry: USD 1295.00,Military/Retired/Scientist/VA : USD 1195.00,Resident/Fellow/Technologist/PA/Nurse: USD 995.00

Speakers: Blake Johnson, MD, John Feller, MD, Adam Flanders, MD, Wende Gibbs, MD, David Polly, MD, Phillip Tirman, MD

Continue reading here:
Mar 4 | Spine Imaging and Intervention in Palm Springs | Palm Desert - Patch.com

DOYLESTOWN, Pa., April 16, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Companys Chairman & CEO, Dean Petkanas, was featured in an OTCQB podcast discussing the cannabinoid therapeutics industry and its role in eradicating the current opioid epidemic.

In the podcast episode, Mr. Petkanas explained how the Companys patented leading drug candidate, KLS-13019, may reduce the use of opioids in the treatment of neuropathic pain. While opioids are considered the standard of care to treat neuropathic pain in the U.S., he spoke of the Companys promising research efforts and the recently published preclinical results showing that KLS-13019 may be a viable non-addictive, non-opioid option to prevent and reverse neuropathic pain. Additional research results have shown that KLS-13019 showed little to no inhibition to six known human opioid targets, whereas cannabidiol (CBD) did show marked and significant inhibition to the same opioid targets.

During the podcast, Mr. Petkanas also discussed Kannalifes original focus on oxidative stress-related diseases like overt hepatic encephalopathy (HE) and how the Company pivoted to chronic pain through a Phase 1 research grant from the National Institutes of Health National Institute on Drug Abuse (NIH-NIDA) to study KLS-13019 as a potential treatment for Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Were grateful for the opportunity to participate in OTC Markets podcast series and to have the ability to share our science and company with the public on the OTCQB, Mr. Petkanas said.

The Company recently completed the STTR phase 1 study funded by the grant from NIDA. The study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative monotherapeutic in the prevention and reversal of CIPN.

About KLS-13019KLS-13019 is Kannalifes leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

About OTC Markets Group Inc.OTC Markets Group Inc. (OTCM) operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market for approximately 10,000 over-the-counter securities. Through OTC Link ATS and OTC Link ECN, OTCM connects a diverse network of broker-dealers that provide liquidity and execution services. OTCM enables investors to easily trade through the broker of their choice and empowers companies to improve the quality of information available for investors.

To learn more about how OTCM creates better informed and more efficient markets, visit http://www.otcmarkets.com.

Story continues

OTC Link ATS and OTC Link ECN are operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

Read more from the original source:
Kannalife, Inc. CEO Featured in OTCQB Podcast Discussing KLS-13019 and Its Potential Role as a Non-Opioid Treatment for Neuropathic Pain - Yahoo...

A new research study has been presented by Industrygrowthinsights.com offering a comprehensive analysis on the Global Diabetic Peripheral Neuropathy Treatment Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Diabetic Peripheral Neuropathy Treatment Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Diabetic Peripheral Neuropathy Treatment Market Report with Latest Industry Trends @ https://industrygrowthinsights.com/request-sample/?reportId=186791

Major Players Covered in this Report are: Achelios Therapeutics IncCelgene CorpCommence Bio IncGrunenthal GmbHImmune Pharmaceuticals IncKPI Therapeutics IncMedifron DBT Co LtdMitsubishi Tanabe Pharma CorpNovaremed LtdReata Pharmaceuticals IncRelief Therapeutics Holding AGViroMed Co Ltd

Global Diabetic Peripheral Neuropathy Treatment Market SegmentationThis market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:AntimunocelASP-8477BNV-222CapsaicinCBX-129801Others

By Applications:HospitalClinicOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=186791

Global Diabetic Peripheral Neuropathy Treatment Market Regions and Countries Level AnalysisRegional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Diabetic Peripheral Neuropathy Treatment on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Diabetic Peripheral Neuropathy Treatment sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Diabetic Peripheral Neuropathy Treatment sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=186791

Why Choose Us:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About Industrygrowthinsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, US.Phone No: US: +1 909 545 6473 | IND: +91-7000061386Email: sales@Industrygrowthinsights.comWebsite: https://Industrygrowthinsights.com

Read the original:
Diabetic Peripheral Neuropathy Treatment Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Surfacing Magazine

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Original post:
Medical Foods Market to Witness Exponential Growth by 2025 - Science In Me

Type 2 diabetes affects insulin in the body. Symptoms of type 2 diabetes include increased thirst, increased hunger, headaches and tiredness. Everybody needs insulin to live and has an essential job to help keep the body healthy. Insulin allows the glucose in the blood to enter the cells and fuel the body. When a person has type 2 diabetes, the body still breaks down carbohydrate from the food and drink and turns it into glucose.

The pancreas responds to this by releasing insulin, however, this insulin cant work properly, and blood sugar levels keep rising and more insulin is released.

This plays havoc on the body with various warning signs that the blood sugar levels are too high.

Left untreated, high blood sugar levels could cause strokes or heart attacks.

There is another side effect to ones health caused by high blood sugars and is knowns as neuropathy.

What is it?

For people with type 2 diabetes, foot complications such as neuropathy and circulation problems can make it difficult for wounds to heal.

Serious problems could arise and other foot issues such as calluses are also common in people with type 2 diabetes.

While calluses may not seem a big problem, left untrimmed they can turn into ulcers or open sores.

People with diabetes are also at risk for Charcot joint, a condition in which a weight-bearing joint progressively degenerates, and this could lead to bone loss or deformity in the feet.

The NHS said: Peripheral neuropathy develops when nerves in the bodys extremities, such as the feet, are damaged.

The symptoms depend on which nerves are affected. In the UK its estimated almost one in 10 people aged 55 or over are affected by peripheral neuropathy.

The main symptoms of neuropathy can include a numbness and tingling in the feet or hands, burning, stabbing or shooting pain in affected areas, loss of balance and co-ordination and muscle weakness, especially in the feet.

These symptoms are usually constant but may come and go.

Read the original here:
Type 2 diabetes: The major warning in your feet due to blood sugar levels being too high - Express

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Physicians in China are reporting what they believe is the first case of COVID-19 initially presenting as acute Guillain-Barre syndrome (GBS). The patient was a 61-year-old woman returning home from Wuhan during the pandemic.

"GBS is an autoimmune neuropathy, which could be triggered by various infections," corresponding author Sheng Chen, MD, PhD, Shanghai Jiao Tong University School of Medicine, China, told Medscape Medical News.

However, "Our single case report only suggests a possible association between GBS and SARS-CoV-2 infection. It may or may not have a causal relationship," Chen noted.

The case study was published online April 1 in Lancet Neurology.

The female patient returned from Wuhan on January 19 but denied having any fever, cough, chest pain, or diarrhea. She presented on January 23 with acute weakness in both legs and severe fatigue that progressed.

At presentation, temperature was normal, oxygen saturation was 99% on room air, and the patient's respiratory rate was 16 breaths per minute. She was not tested for SARS-CoV-2 at that point.

A neurologic examination revealed symmetric weakness (Medical Research Council grade 4/5) and areflexia in both legs and feet. The patient's symptoms had progressed 3 days after admission, and testing revealed decreased sensation to light touch and pinprick.

Admission laboratory test results indicated a low lymphocyte count and thrombocytopenia. Results of nerve conduction studies performed on day 5 of hospitalization were consistent with demyelinating neuropathy.

She was diagnosed with GBS and given intravenous immunoglobulin. On day 8, she developed a dry cough and fever, and a chest CT showed ground-glass opacities in both lungs. At this point, she was tested for SARS-CoV-2, and the results were positive.

The patient was immediately transferred to an isolation room and received supportive care and antiviral drugs. Her condition improved gradually, and her lymphocyte and thrombocyte counts were normalon day 20.

At discharge on day 30, she had normal muscle strength in both arms and legs, and tendon reflexes in both legs and feet had returned. Her respiratory symptoms had resolved as well. A second SARS-CoV-2 test was negative.

Two relatives of the patient who had been with her during her hospital stay also tested positive for SARS-CoV-2 and were isolated and treated.

All of the hospital staff that cared for the patient, including two neurologists and six nurses, tested negative for SARS-CoV-2.

Given the temporal association, SARS-CoV-2 infection could be responsible for the development of GBS in this patient, the investigators note. They add that the onset of GBS symptoms overlapped with the period of SARS-CoV-2 infection.

"Hence Guillain-Barre syndrome associated with SARS-CoV-2 might follow the pattern of a parainfectious profile, instead of the classic postinfectious profile, as reported in Guillain-Barre syndrome associated with Zika virus," the researchers write.

"More cases with epidemiological data are necessary to support a causal relationship" between SARS-CoV-2 infection and GBS, said Chen.

"However, we still suggest physicians who encounter an acute GBS patient from a pandemic area protect themselves carefully and test [for the] virus on admission. If the result is positive, the patient needs to be isolated," Chen said.

Lancet Neurol. Published online April 1, 2020. Full text

For more Medscape Neurology news, join us on Facebook and Twitter.

More here:
First Case of COVID-19 Presenting as Guillain-Barr Reported - Medscape

Latest Report onPeripheral Neuropathy Treatment Market

The report titled Global Peripheral Neuropathy Treatment Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Peripheral Neuropathy Treatment market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Peripheral Neuropathy Treatment market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Peripheral Neuropathy Treatment market is carefully analyzed and researched about by the market analysts.

Peripheral Neuropathy Treatment Market competition by top manufacturers/ Key player Profiled: Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Aptinyx, Regenacy Pharmaceuticals

Request a sample copy of the report with Detail TOC and List of Figures @ https://www.alexareports.com/report-sample/689123

Global Peripheral Neuropathy Treatment Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2024. According to the latest report added to the online repository of Alexareports the Peripheral Neuropathy Treatment market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2024.

Peripheral Neuropathy Treatment Market Segment by Type covers: Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others

Peripheral Neuropathy Treatment Market Segment by Application covers:Platinum Agents, Taxanes, Vinca Alkaloids, Others

After reading the Peripheral Neuropathy Treatment market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Peripheral Neuropathy Treatment market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalPeripheral Neuropathy Treatment market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Peripheral Neuropathy Treatment market?What are the key factors driving the global Peripheral Neuropathy Treatment market size?Who are the key manufacturers in Peripheral Neuropathy Treatment market space?What are the market opportunities, market risk and market overview of the Peripheral Neuropathy Treatment market?What are sales, revenue, and price analysis of top manufacturers of Peripheral Neuropathy Treatment market?Who are the distributors, traders, and dealers of Peripheral Neuropathy Treatment market?What are the Peripheral Neuropathy Treatment market opportunities and threats faced by the vendors in the global Peripheral Neuropathy Treatment industries?What are sales, revenue, and price analysis by types and applications of Peripheral Neuropathy Treatment market?What are sales, revenue, and price analysis by regions of Peripheral Neuropathy Treatment industries?

GetExclusive discount on this report now at https://www.alexareports.com/check-discount/689123

Some of the Major Highlights of TOC covers:

Peripheral Neuropathy Treatment Regional Market Analysis

Peripheral Neuropathy Treatment Production by RegionsGlobal Peripheral Neuropathy Treatment Production by RegionsGlobal Peripheral Neuropathy Treatment Revenue by RegionsPeripheral Neuropathy Treatment Consumption by RegionsPeripheral Neuropathy Treatment Segment Market Analysis (by Type)

Global Peripheral Neuropathy Treatment Production by TypeGlobal Peripheral Neuropathy Treatment Revenue by TypePeripheral Neuropathy Treatment Price by TypePeripheral Neuropathy Treatment Segment Market Analysis (by Application)

Global Peripheral Neuropathy Treatment Consumption by ApplicationGlobal Peripheral Neuropathy Treatment Consumption Market Share by Application (2014-2020)Peripheral Neuropathy Treatment Major Manufacturers Analysis

Peripheral Neuropathy Treatment Production Sites and Area ServedProduct Introduction, Application and SpecificationPeripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2020)Main Business and Markets Served

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/689123

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

See the original post here:
(2020-2025) Peripheral Neuropathy Treatment Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,...

Sensory loss can lead to isolation and depression

DOTHAN, Ala. (AP) Caring for a 101-year-old man whos deaf and almost totally blind takes patience and understanding.

Its the kind of work Nancy Griffin finds rewarding.

As one of the caregivers with Wiregrass Area Home Instead Senior Care looking after the man and his wife, Griffin sees the challenges people with sensory loss face.

She also recognizes that creating a supportive environment to help them live a fulfilling life is vital.

To see how they enjoy each other every day, it makes your heart smile, Griffin said.

A recent survey by Home Instead found that approximately 83% of U.S. adults 65 and older are living with at least one diminished sense.

Sensory impairments can lead to feelings of isolation and depression, and diminish a persons quality of life.

One of the things we see with these challenges or deprivations in senses is that a lot of people become withdrawn because they cant communicate, said Liz Woodard, a community service representative with Home Instead. They cant hear or they cant see so they tend to isolate and withdraw.

A decline in any of the five senses taste, smell, touch, hearing and sight can affect a persons well-being.

One in 5 adults 65 and older have partially lost their sense of taste, Woodard said. It leads to poor nutrition, loss of appetite, which also leads to decline in our seniors.

A diminished sense of smell can cause some seniors to eat too little or too much.

Damaged nerves, known as neuropathy, in the hands and feet can cause tingling, numbness, weakness and pain. The damage makes walking and other tasks difficult.

If somebody has diabetic neuropathy or neuropathy caused by something else, their ability to feel the floor could lead to injury from them knocking and hurting and injuring their feet, Woodard said.

Inner ear problems can affect hearing and balance. Impaired vision reduces a persons ability to perform daily tasks and move about unaided.

Because your depth perception is off you may not see your slippers that are right there on the floor and trip over them, or your little dog, Woodard said.

SOURCE OF HELP

Impaired senses and mobility can be debilitating for older adults. Southern Alabama Regional Council on Aging provides services to enhance the independence of seniors in Barbour, Coffee, Covington, Dale, Geneva, Henry and Houston counties.

Alicia Anderson, a long-term care ombudsman at SARCOA, said the organization offers age play training that can be geared toward nursing homes, groups and the public.

It kind of simulates the aging process, Anderson said. It goes over things like visual impairment, hearing loss, dementia.

The training helps people understand what its like to have diminished capabilities. The sessions are useful for anyone who deals with the elderly or disabled.

Griffin started working with the couple in 2017. The man and his wife, who will turn 95 in late May, were in the hospital with the flu and were about to be discharged.

Thats when the daughter contacted Home Instead, because they were both weak and needed 24-7 care, Griffin said.

Caregivers provide a variety of services that allow seniors to remain in their homes.

We help them bathe. We fix their meals. We keep their home clean, she said.

Griffin said being paired with the couple was a godsend because theyre like my grandparents.

She discovered right off the bat that the wife ran the house.

You have to respect that youre going into their home, Griffin said. You have to respect them. You cant go in and start rearranging furniture or telling them what theyre going to do. You dont do that. You go in, you respect them, and you do what they ask you to do.

Woodard said that approach is essential.

Were working with adults, not children, Woodard said.

Part of the job involves knowing what a client can and cannot do. Sensory-impairment kits let caregivers experience the challenges faced by people with sensory loss and other conditions, whether its opening a pill bottle or dealing with impaired vision.

Because the client cant hear and has poor vision, caregivers devised ways to communicate with him.

We have three of the white boards that we use a dry-erase marker on, Griffin said.

Questions can be answered with hand taps a tap on the back indicating yes and a tap on the wrist indicating no.

Every day, the man and his wife enjoy a game of Scrabble.

That is their time, every afternoon around 3 oclock before the 5 oclock news, Griffin said.

The news is the only time their television is turned on.

Otherwise were interacting with them on a daily basis, Griffin said.

The client loves paint-by-number.

To be 101, his hand is extremely steady, Griffin said. You know how tiny the spots are on a paint-by-number? He gets into those lines; he is so steady.

He also enjoys playing card and dice games.

He likes to play craps of all things, and he usually wins, Griffin said.

The man used to be a world traveler. He was a bachelor until age 54 when he married his wife, who had been married before.

We have watched several times his disc of his traveling out West, down South, up North, Griffin said. He has climbed mountains.

The couples optimism is inspiring. Griffin said they give me the best day that I can possibly have, honestly. I am constantly learning from them.

MULTIDIMENSIONAL JOB

Woodard said being a caregiver means looking after more than just the physical needs.

Its great that even with these challenges were still able to socially engage and to have some fun and to have some quality of life even with these challenges that our seniors face, she said.

Home Instead offers free resources and tools on its agingsenses.com website to help people understand the challenges of sensory loss. The website includes tips on things you can do to protect your senses and has an interactive video that lets you experience baking with vision loss.

Read the original:
Sensory loss can lead to isolation and depression - Thehour.com

Chemotherapy Induced Peripheral Neuropathy (CIPN) MarketLatest Research Report 2020:

The Chemotherapy Induced Peripheral Neuropathy (CIPN) report provides an independent information about the Chemotherapy Induced Peripheral Neuropathy (CIPN) industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Chemotherapy Induced Peripheral Neuropathy (CIPN) Market: Products in the Chemotherapy Induced Peripheral Neuropathy (CIPN) classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Company I, Company II, Company III, Company IV and more

Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Report Covers the Following Segments:

Segment by Type:Type I, Type II, Type III

Segment by Application:Application I, Application II, Application III

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Chemotherapy Induced Peripheral Neuropathy (CIPN) Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market.

Market Forecast:Here, the report offers a complete forecast of the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://brandessenceresearch.com/technology-media/global-antivirus-software-market-2018-2024

https://brandessenceresearch.com/agriculture/seed-treatment-fungicides-market-rising

https://brandessenceresearch.com/consumer-goods/global-steam-generator-irons-market-2014-2024

https://brandessenceresearch.com/consumer-goods/global-steam-generator-irons-market-2014-2024

https://www.marketwatch.com/press-release/speciality-chemicals-marketglobal-industry-analysis-size-share-growth-trends-and-forecast-20202025-2020-04-10

Read more:
Coronavirus Outbreak: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Strategies and Insight Driven Transformation 2020-2025 - Curious Desk

QY Research has recently curated a research report titled, Global Diabetic Neuropathy Drugs Market Research Report 2020. The report is structured on primary and secondary research methodologies that derive historic and forecast data. The global Diabetic Neuropathy Drugs market is growing remarkably fast and is likely to thrive in terms of volume and revenue during the forecast period. Readers can gain insight into the various opportunities and restraints shaping the market. The report demonstrates the progress and bends that will occur during the forecast period.

Global Diabetic Neuropathy Drugs Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global market and also about each type from 2015 to 2026. This section mentions the volume of sales by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601446&source=atm

Competitive Landscape:

The analysts have provided a comprehensive analysis of the competitive landscape of the global Diabetic Neuropathy Drugs market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

The key players covered in this studyPfizerNovartisJohnson & JohnsonEli LillyGlaxoSmithKlineBoehringer IngelheimTeva PharmaceuticalDaiichi SankyoAstellas Pharma

Market segment by Type, the product can be split intoCalcium Channel Alpha-2 Delta LigandSNRIs and TCAsOthersMarket segment by Application, split intoHospitalsDrug StoresOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Diabetic Neuropathy Drugs status, future forecast, growth opportunity, key market and key players.To present the Diabetic Neuropathy Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Diabetic Neuropathy Drugs are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601446&source=atm

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

Global Diabetic Neuropathy Drugs Market: Segment Analysis

The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Global Diabetic Neuropathy Drugs Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, China, and Japan alone. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601446&licType=S&source=atm

See the rest here:
Diabetic Neuropathy Drugs Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 - Jewish Life News

There is a close association between sarcopenia and diabetic peripheral neuropathy (DPN), according to study results published in Diabetes Research and Clinical Practice.

Sarcopenia may lead to reduced exercise and increased risk for microvascular complications in patients with diabetes mellitus, including nephropathy and retinopathy. Because there is little information on the association between sarcopenia and DPN, the goal of the current cross-sectional study was to explore this association. In addition, a cohort study was carried out to investigate the changes in muscle mass and nerve conduction velocity.

The cross-sectional study included 1794 individuals (937 men; mean age, 60.22 years). Of these, 183 patients (98 men; mean age, 59.08 years) were enrolled in the follow-up study with a median follow-up of 2.7 years.

All patients underwent nerve conduction tests and muscle mass index was calculated using the following formula: appendicular skeletal muscle mass (ASM; in kg) divided by height squared (HT2; in m2 [ASM/HT2]). The composite z scores for the sensory nerve conduction velocity (SCV) and motor nerve conduction velocity (MCV) were calculated. The changes in ASM/HT2, SCV, and MCV were calculated from the measurements approximately 2 years apart and changes in skeletal muscle were classified into 3 groups: a decrease in ASM/HT2 of >3%, a minor change within 3%, or an increase of >3%.

In men, the multivariate regression analysis showed that muscle mass index was positively associated with the median (=0.928; P <.001), ulnar (=1.462; P <.001), peroneal (=1.059; P =.001), and tibial MCV (=0.839; P =.001) among the motor neurons; the median (=1.499; P <.001), ulnar (=0.837; P =.044), peroneal (=2.090; P =.002), and sural SCV (=1.257; P =.014) among the sensory neurons; and the composite z scores of MCV (=0.197; P <.001) and SCV (=0.3000; P <.001).

Receiver operating characteristic analysis indicated that the optimal cutoff point for ASM/HT2 that indicated DPN was 7.09 kg/m2 (area under the curve, 0.605; 95% CI, 0.569-0.642; sensitivity, 53.1%; specificity, 72.3%).

No significant correlations were found between ASM/HT2 and MCV, SCV and neuropathy score, and DPN and sarcopenia in women.

In the follow-up cohort study, there was a strong positive association between 2-year changes in skeletal muscle and nerve conduction velocity. During the follow-up period, nerve conduction velocity increased in terms of the partial motor and sensory velocities with an increase in the muscle mass in men with diabetes. However, similar to the findings in the cross-sectional analysis, this phenomenon was generally not observed in women with diabetes.

The researchers noted several limitations to the study, including possible selection bias as the study was performed in a hospital and included mainly middle-aged adults with nonsevere diabetes. As such, the findings may not be generalizable to older patients.

The assessment of muscle mass may have clinical implications in the prevention of DPN in men with diabetes, concluded the researchers.

Reference

Zhang Y, Shen X, He L, Zhao F, Yan S. Association of sarcopenia and muscle mass with both peripheral neuropathy and nerve function in patients with type 2 diabetes [published online February 25, 2020]. Diabetes Res Clin Pract. doi:10.1016/j.diabres.2020.108096

This article originally appeared on Endocrinology Advisor

View post:
Close Association Between Diabetic Peripheral Neuropathy and Sarcopenia - Neurology Advisor

By Elizabeth Martin

More than 39 percent of the population will be diagnosed with cancer at some point in their life, so chances are, someone you know has had cancer. A 2019 study in JAMA Oncology found that acupuncture was significantly associated with lower pain levels for cancer patients. It seems that recently Eastern medicine, such as acupuncture, is integrating with Western medicine. The ongoing opioid crisis makes it more challenging to address cancer pain management, making acupuncture an alternative for pain.

One of the common side effects of chemotherapy is neuropathy, where nerve damage causes tingling, numbness and other sensations that can be extremely uncomfortable. This pain is often not treated or cant be treated with pain medication, but acupuncture proves to be a great alternative. Acupuncture and Chinese Medicine help open the body up and heal by promoting the flow of Qi (our vital energy). Acupuncture helps to bring circulation and blood flow to certain areas, helping the body to heal itself.

As a practitioner, I hear over and over that cancer patients are apprehensive about taking another medication for the side effects of another medication. But acupuncture is a noninvasive way to treat these side effects. I already mentioned that acupuncture helps with neuropathy because it stimulates blood flow to the damaged nerves. With nausea and loss of appetite, acupuncturists can open up channels that lead to the stomach meridian to help the body work more efficiently and improve the flow of energy to that area.

When someone has insomnia, its a sign that the brain is not shutting off. Acupuncture tells the neurotransmitters in the brain to calm down and helps to reprogram your bodys own circadian rhythm. When we are working on patients with insomnia, most of the time we choose to work on the heart meridians, because the heart calms the mind, and in traditional Chinese medicine we believe it is connected to the mind and spirit.

Often, schedules are packed with doctors appointments, but a visit to the acupuncturist is one to look forward to. I wanted my office to feel like home, so I purposely designed my practice to be that way, touching on the five elements of Chinese Medicine: wood, water, fire, earth, and metal and making it a tranquil, medical spa-like atmosphere. Doctors often look at their patients like a number, rushing to get them in and out of the door, but during an acupuncture appointment at our practice, we make a point to spend the time to get to know our patients and help to talk them through the emotions they may be going through during their cancer diagnosis and treatment.

Elizabeth Martin

The theory is that acupuncture is compared to going for a runincreasing circulation, draining the lymph nodes, and releasing toxins. Whenever you get acupuncture, it releases neurotransmitters in the brain like serotonin and epinephrine, which helps boost energy levels and improve mood. At the practice we also use acupuncture to help treat allergies, as it goes back to my earlier point about opening the flow of Qi.

With the treatments and appointments that many cancer patients are already going to, they can often be afraid and apprehensive to try acupuncture while in treatment. But in fact, this is the best time to go. We often hear from our cancer patients that they felt overwhelmed with adding another appointment, but after coming to acupuncture they felt more relaxed, had less pain, and felt calmer after undergoing regular acupuncture treatments. Often the patients that were skeptical of acupuncture would take a break and very often when stopping acupuncture regularly, it caused their pain to return.

Acupuncture is only one pillar of Chinese Medicine, but other modalities include manual therapy, Chinese herbal medicine, and meditation practices like Qi gong. A recent meta-analysis in patients with cancer and insomnia showed that yoga, meditation, hypnosis, mindfulness-based stress reduction, and qi gong have a moderate effect on the improvement of sleep quality for up to three months. At my practice, we also do sound healing classes, which has been a great way to start meditation and can help reduce stress. This practice uses vibrations (vocal or instrumental-like gongs, Tibetan singing bowls and tuning forks) in order to relax your mind and body.

Elizabeth Martin is a board-certified licensed acupuncturist. She is the owner of Hands On Acupuncture and Massage Therapy PC on Long Island. Visit http://www.handsonacupuncture.com to learn more.

See the rest here:
Six Benefits Of Acupuncture For Cancer Patients - Long Island Weekly News

With having published myriads of reports, Diabetic Peripheral Neuropathy Treatment Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, Diabetic Peripheral Neuropathy Treatment Market Research serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Diabetic Peripheral Neuropathy Treatment market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Diabetic Peripheral Neuropathy Treatment market.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2251608&source=atm

The Diabetic Peripheral Neuropathy Treatment market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The following manufacturers are covered:Achelios Therapeutics IncCelgene CorpCommence Bio IncGrunenthal GmbHImmune Pharmaceuticals IncKPI Therapeutics IncMedifron DBT Co LtdMitsubishi Tanabe Pharma CorpNovaremed LtdReata Pharmaceuticals IncRelief Therapeutics Holding AGViroMed Co Ltd

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeAntimunocelASP-8477BNV-222CapsaicinCBX-129801Others

Segment by ApplicationHospitalClinicOthers

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2251608&source=atm

What does the Diabetic Peripheral Neuropathy Treatment market report contain?

Readers can get the answers of the following questions while going through the Diabetic Peripheral Neuropathy Treatment market report:

And many more

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2251608&licType=S&source=atm

For More Information Kindly Contact:

ResearchMoz.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read more:
Diabetic Peripheral Neuropathy Treatment Market Industry Production and Demand, Competition News and Trends Forecasts to 2024 - Jewish Life News